Last reviewed · How we verify
Faropenem Daloxate (faropenem medoxil)
Faropenem Daloxate (generic name: faropenem medoxil) is a drug. It is currently in unknown development for Bacterial infection of skin, Respiratory tract infection.
Faropenem Daloxate works by inhibiting bacterial cell wall synthesis.
Faropenem Daloxate is a small molecule inhibitor of bacterial penicillin-binding protein. It has been studied as a treatment for conditions such as otitis media and chronic bronchitis.
At a glance
| Generic name | faropenem medoxil |
|---|---|
| Therapeutic area | Metabolic |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are like houses, and bacteria are like unwanted guests. Faropenem Daloxate helps keep the guests from building new houses by blocking the tools they need to do so, ultimately leading to their demise.
Approved indications
- Bacterial infection of skin
- Respiratory tract infection
Common side effects
Key clinical trials
- A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis (PHASE3)
- A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Faropenem Daloxate CI brief — competitive landscape report
- Faropenem Daloxate updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Faropenem Daloxate
What is Faropenem Daloxate?
How does Faropenem Daloxate work?
What is Faropenem Daloxate used for?
What is the generic name of Faropenem Daloxate?
What development phase is Faropenem Daloxate in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Bacterial infection of skin
- Indication: Drugs for Respiratory tract infection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing